GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?
Meng-Wong Taing,1,2 Felicity J Rose,1,3 Jonathan P Whitehead11Metabolic Medicine, Mater Research Institute, University of Queensland, 2School of Pharmacy, University of Queensland, Brisbane, QLD, Australia; 3University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Q...
Saved in:
Main Authors: | Taing MW (Author), Rose FJ (Author), Whitehead JP (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2014-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Glucagon-like peptide 1 (GLP-1)
by: T.D. Müller, et al.
Published: (2019) -
OCT1 Polyspecificity-Friend or Foe?
by: Marleen J. Meyer, et al.
Published: (2021) -
Effects of exercise on glucagon-like peptide-1 (GLP-1)
by: Shin-ya Ueda, et al.
Published: (2013) -
Glucagon-like peptide-1 (GLP-1) agonists in the treatment of obesity
by: Magdalena Mazurek, et al.
Published: (2023) -
TAK1 in Vascular Signaling: “Friend or Foe”?
by: Fan G, et al.
Published: (2024)